Advertisement |
We know that not every patient with influenza gets a diagnosis of flu. We think our 540 number is a better estimate
CDC estimates 22M had H1N1, 3,900 died Nov 12, 2009
With those two surveillance symptoms, we are then extrapolating to the whole United States and the entire period of this first six months
CDC estimates 22M had H1N1, 3,900 died Nov 12, 2009
We know that flu -- and specifically H1N1 this year -- is a big concern for people, but flu shouldn't ruin the holidays
CDC tells travelers to 'Stop, Wash and Go' Nov 19, 2009
The study that was reported was one single study with one particular vaccine in one population at one point in time
CDC: 60 million in U.S. had H1N1 vaccine Dec 22, 2009
All Americans can now get immunized so we're encouraging people to take advantage of the increased supply to protect themselves and protect their loved ones -- particularly ones with diabetes, heart disease, cancer, pregnancy, to take advantage of the vaccine
Ga. H1N1 'intense,' CDC urges vaccine Mar 29, 2010
Rear Admiral Anne Schuchat, M.D., is the current Interim Deputy Director for Science and Public Health Program at the Centers for Disease Control and Prevention (CDC).
Anne Schuchat graduated with highest honors from Swarthmore College and with honors from Dartmouth Medical School. She served as resident and chief resident in internal medicine at New York University′s Manhattan VA Hospital before beginning her public health career at CDC as an Epidemic Intelligence Service (EIS) officer in NCID.
As Interim Deputy Director for Science and Public Health Program, Dr. Schuchat is focused on ensuring strong science and programmatic approaches are effectively integrated into planning across the agency. She has emphasized prevention of infectious diseases in children. Her emphasis on perinatal group B streptococcal disease prevention has led to an 80 percent reduction in newborn infections and a 75 percent narrowing of racial disparities among sufferers of this infectious disease. She has been instrumental in pre- and post-licensure evaluations of conjugate vaccines for bacterial meningitis and pneumonia and in accelerating availability of these new vaccines in resource-poor countries through WHO and the Global Alliance for Vaccines and Immunization.